BofA Lowers Definitive Healthcare Target to $3.50

BofA cut Definitive Healthcare's price target to $3.50 from $4.00, citing weaker 2026 guidance and lower EBITDA multiple.
Q4 revenue rose 3% and adjusted EBITDA 9% above consensus, but total customers fell to 2,330, down from 2,400.
FY2025 Q4 revenue hit $61.5 million beating estimates, yet EPS was –$0.09 versus the forecast $0.06.
Board member Jeff Haywood resigned, ending Spectrum nominating agreement and reducing the board to eight directors.